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ABSTRACT 
 
The genome is constantly damaged by intracellular and extracellular factors. At 
sites of DNA damage, replication forks are stalled, leading to monoubiquitination of 
proliferating cell nuclear antigen (PCNA). Monoubiquitination of PCNA promotes the 
switch from regular high-fidelity polymerases to Y-family polymerases for bypassing 
damaged DNA. Prolonged replication by these polymerases may lead to increased 
mutagenesis, so tight regulation of this process is required. ATAD5 recruits a 
deubiquitinase complex consisting of ubiquitin-specific protease 1 (USP1) and USP1-
associated factor 1 (UAF1) to control PCNA monoubiquitination. The mechanism by 
which ATAD5 and PCNA interact has been previously unexplored. We show through 
biochemical and structural studies that ATAD5 contains a non-canonical PCNA-
interacting protein motif that interacts with PCNA in the low µM range. Our structural 
studies indicate that the binding of ATAD5’s PIP Box to PCNA is topologically conserved 
with respect to canonical PIP Boxes from other proteins. Furthermore, we detected we 
interactions between ATAD5’s and UAF1’s protein interacting motifs. This suggests that 
ATAD5 acts as an adapter between PCNA and the UAF1-USP1 deubiquitinase complex. 
Characterization of these interactions will increase our understanding of DNA damage 
tolerance and may lead to the design of better cancer therapeutics.  
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CHAPTER 1: INTRODUCTION 
1.1 Translesion DNA Synthesis 
 Faithful replication of a cell’s genetic material during replication is essential in 
order to pass genetic material from one generation to the next; however, DNA-damaging 
agents constantly injure the genome. High fidelity replication of the cell’s genetic material 
is normally carried out through the combination of accurate DNA polymerases and DNA 
mismatch repair (1). These high-fidelity DNA polymerases have evolved mechanisms to 
strongly favor correct dNTP incorporation opposite to the template strand during 
replication (1). However, these polymerases are unable to replicate past damaged DNA, 
and are stalled at these sites (2). Stalled replication forks are dangerous as they can collapse, 
causing chromosomal breaks and genomic instability (3). 
Cells belonging to all branches of life possess DNA damage tolerance (DDT) 
pathways in order to survive in the presence of DNA-polymerase blocking lesions and to 
restart stalled replication forks (4). One of the DDT pathways is the translesion synthesis 
(TLS) pathway, which involves the use of specialized DNA polymerases, most of which 
belong to the Y-family (5). Y-family polymerases differ from other polymerases in that 
they are able to replicate past DNA lesions and have reduced fidelity on undamaged 
templates (6). Prolonged replication by these low-fidelity polymerases could have 
deleterious consequences arising from mutations, so it is crucial that their activity is strictly 
regulated (6). The specific mechanism in which different polymerases are loaded on and 
off of the replication fork involves post-translational modification of proliferating cell 
nuclear antigen (PCNA) (7). 
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1.2 Proliferating Cell Nuclear Antigen 
 PCNA is a DNA sliding clamp with multiple functions in DNA replication and 
repair. Two separate groups first identified PCNA independently from each other. The first 
group, Miyachi et al. (1978), observed an auto-antigen in the nucleus of dividing cells from 
patients with systemic lupus erythematosus and named it PCNA (8). The second group, 
Bravo and Celis (1980), identified a protein that was synthesized during the S-phase of the 
cell cycle using two-dimensional gel electrophoresis and named it cyclin (9). Work by 
Mathews et al. (1984) later demonstrated that the two proteins discovered by these groups 
were the same (10). Today the protein is called PCNA, as the term cyclin is now reserved 
for a family of proteins involved in cell cycle regulation (11).  
PCNA has functions at various levels of DNA metabolic pathways while unbound 
or bound to DNA. When unbound to DNA, PCNA promotes the localization of replication 
factors with PCNA-binding domains to replication factories (12). When bound to DNA, 
PCNA directs proteins involved in DNA replication, repair, modification, and chromatin 
modeling (12). PCNA is the processivity factor of Polδ and is therefore the functional 
homologue of other processivity factors such as the β subunit of E. coli DNA polymerase 
III holoenzyme  (Pol III) and the gene-45 product of bacteriophage-T4 (11). Stukenberg et 
al. (1991) first established the concept that a processivity factor functions by encirculating 
DNA through experiments on the β subunit of E. coli Pol III (13). They demonstrated that 
the β subunit bound tightly to nicked circular plasmid, however, the clamp dissociates off 
of  DNA by sliding over the ends upon linearization of the plasmid (13). The determination 
of the crystal structure of the β subunit confirmed these studies and revealed that it is a 
homodimeric ring (14).  
  
3 
1.2.1 Human PCNA Structure 
 The ortholog of the β subunit of Pol III in eukaryotes is PCNA.  Although the 
sequence similarity between these two proteins is limited, they are structurally similar. 
Human PCNA consists of three identical monomers instead of two (Figure 1A) (15). Each 
monomer of human PCNA contains two similar domains, giving the complete protein a 
six-fold pseudo symmetry (Figure 1C) (12). Each of the domains is composed of a series 
of antiparallel β strands forming curved β sheets. Six curved β sheets make up a donut-like 
scaffold. Two alpha helices from each domain face inward approximately perpendicular to 
the face of the ring to form a cylindrical inner cavity with a diameter of about 34 Å. This 
is much larger than the diameter of double stranded B DNA (20 Å). Although PCNA has 
a net negative charge, the inner cavity is electrostatically positive. Up to 10 positively 
charged amino acid side chains face toward the center from the alpha helices, however, 
there are only three negatively charged amino acids to counteract the charge. The positively 
charged ring forms favourable interactions through the solvent to the negatively charged 
phosphodiester backbone of DNA (12).  
PCNA has a distinct back and front face (Figure 1B). The front face of PCNA is 
oriented in the direction of DNA synthesis and contains structural elements that are 
involved in many protein interactions (16). The C-terminal tails of the monomers face 
frontward along with an interdomain connecting loop (IDCL) which links the N- and C- 
terminals of each monomer (12). The IDCL covers a hydrophobic pocket, which can be 
“plugged” by proteins containing a PCNA-interaction protein motif (PIP box) (15). 
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Figure 1. Structure of native human PCNA (PDB ID: 1W60). Each monomer is coloured 
differently. A) Cartoon representation with transparent surface of the front (top) and back 
(bottom) view of PCNA showing the diameter of the inner ring. B) Side view of PCNA 
with the front and back labelled. C) Front view of PCNA monomer. The two similar 
globular domains have been divided by a dotted line. N- and C- terminals are indicated in 
bold. 
A B 
C 
34Å 
Front 
Back 
Front Back 
N 
C 
  
5 
1.2.2 PCNA-interacting protein motif (PIP box) 
Virtually all proteins that interact with PCNA contain a PCNA-interacting protein 
motif termed the “PIP box”. The consensus binding motif of the PIP box is: 
Qxx[Ψ]xx[ϑ][ϑ] (x being any amino acid, ψ being the hydrophobic residues L, M, or I and 
ϑ being the aromatic residues F or Y (17). In some cases, instead of being C-terminally 
flanked by xx[ϑ][ϑ], the Qxx[Ψ] motif can be flanked by KAx instead (18). A sequence 
alignment of human proteins that interact with PCNA is shown in Figure 2. Gulbis et al. 
(1996) first published a crystal structure that revealed how the PIP box interacts with 
PCNA using a peptide derived from p21WAF1/CIP1 (p21), an inhibitor of the cyclin-
dependent kinases that control the initiation of S phase and DNA replication (19). This 
peptide binds PCNA with high affinity, the interaction has a Kd in the low nanomolar range 
(15, 20). The PIP box of this peptide was shown to form an alpha helix that acts as a 
hydrophobic plug, docking into the hydrophobic pocket on PCNA. Furthermore, the C-
terminal of this peptide forms a β sheet structure that makes extensive contacts with the 
IDCL (15). Proteins that interact with PCNA through a PIP box may also use additional 
regions for interaction (21). Because many proteins that contain PIP boxes bind to PCNA 
in the same region, the binding is often mutually exclusive and competitive (21). 
Many of the pathways which PCNA is part of involves the transfer of DNA from 
one enzyme to another. For example, during Okazaki fragment processing, FEN1 must 
cleave the 5’ flap on DNA before DNA ligase can patch the nick (22). One possibility of 
how this occurs is that PCNA acts as a “toolbelt”, binding all the necessary enzymes 
required to facilitate the transfer of the substrate (22). This has been observed in  
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     Consensus   QxxΨxxϑϑ 
 
p21    RKRRQTSMTDFYHSKR 
Poi∂   KANRQVSITGFFQRK- 
FEN1   QGSTQGRLDDFFKVTG 
WRN    IEGDQWKLLRDFLLRD 
RecQ   KEEAQNLIRHFFHGRA 
MSH6   -MSRQSTLYSFFPKSP 
MSH3   APARQAVLSRFFQSTG 
Ligl   ---MQRSIMSFFHPKK 
UNG2   -MIGQKTLYSFFSPSP 
 
RFC    -----MDIRKFFGVIP 
Polι   --CAKGLIDYYLMPSL 
Polη   RPEGMQTLESFFKPLT 
Polκ   PNPPKHTLDIFFK--- 
ATAD5  APPKPSNILDYFRKTS 
 
 
Figure 2. Sequence alignment of human proteins containing PIP boxes. The consensus 
sequence is shown with the alignment, where x being any amino acid, ψ being the 
hydrophobic residues L, M, or I and ϑ being the aromatic residues F or Y. Canonical PIP 
box residues are coloured blue at positions 1, 4, 7 and 8. Canonical and non-canonical PIP 
boxes are separated.  
 
  
  
7 
S. solfataricus where a PCNA heterotrimer simultaneously binds to DNA polymerase, 
FEN1, and DNA ligase (23). However, There is currently no clear evidence that suggests 
eukaryotic PCNA functions as a toolbelt, however, it is likely (22).  
 
1.2.3 Post-translational modification of PCNA 
 PCNA is post-translationally modified in response to stalling of the replication fork 
via sumoylation or monoubiquitination (24). As previously mentioned, prolonged stalling 
of the replication fork during DNA replication is dangerous as it can collapse. This causes 
double-stranded breaks and gross chromosomal rearrangements which may lead to cell 
death (3). Restart of the replication fork is possible through post-translational modification 
of PCNA and subsequent activation of one of two DDT pathways. These pathways include 
the homologous recombination repair pathway through sumoylation of K164 or the post-
replication repair pathway via monoubiquitination of the same lysine residue (25, 26). As 
seen in Figure 3A, monoubiquitination of K164 is carried out by E2 ubiquitin conjugating 
enzyme Rad6 and E3 ubiquitin ligase Rad18 (Rad6/Rad18 complex) in the RAD6 pathway 
(25). Rad18 recruits the ubiquitination machinery to DNA-bound PCNA through 
interactions with Rad6, PCNA, and DNA (27). The structure of mono-ubiquitinated PCNA 
is shown in Figure 3B.  
Monoubiquitinated PCNA (ubPCNA) has been proven to promote TLS carried out 
by Y-family polymerases. In addition to the PIP box motif, these polymerases also contain 
ubiquitin-binding motifs (UBMs) or ubiquitin-binding zinc fingers (UBZ) which are able 
to interact with the ubiquitin moiety and increase its affinity to ubPCNA (24). Tight 
regulation of TLS polymerases is required, as prolonged replication by these error-prone   
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Figure 3.  PCNA ubiquitination is regulated by the RAD6 pathway and the UAF1-USP1. 
A) PCNA is monoubiquitinated through the Rad6 pathway and deubiquitinated through the 
recruitment of the UAF1-USP1 deubiquitinase (DUB) complex. B) Structure of 
monoubiquitinated PCNA (PDB ID: 3TBL). Ubiquitin molecules (orange) are covalently 
linked to K164 of PCNA (blue) on two of three monomers.   
  
Rad6/ 
Rad18 
UAF1-USP1 
A 
B 
Ubiquitin Ubiquitin 
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polymerases may lead to increased mutagenesis. Zhuang et al. (2008) demonstrated that 
the switching from the TLS polymerase η (Polη) to the normal high-fidelity Polδ is 
inhibited by the ubiquitin moiety on PCNA (28). This suggests that deubiquitination is 
required for the normal high-fidelity polymerase to switch back to DNA synthesis after 
lesion bypass. Ubiquitin specific protease 1 (USP1) was identified in a siRNA screen as a 
putative deubiquitinase (DUB) for PCNA (29).  
 
1.3 Ubiquitin-Specific Protease 1 (USP1) and USP1 Associated Factor (UAF1) 
Complex 
 DUB enzymes control deubiquitination of human proteins. Although 95 distinct 
proteins belong to this family of proteins, many of their functions are unknown (30). DUBs 
are cysteine proteases that remove ubiquitin from their substrate, either from mono- or 
poly- ubiquitinated proteins or from linear ubiquitin polypeptides (29).  
 USP1 is a DUB that negatively regulates PCNA monoubiquitination in vivo and in 
vitro (29). Upon DNA damage, transcription of USP1 is immediately turned off leading to 
a rapid decay of USP1. This allows for PCNA to become monoubiquitinated, which is 
essential for translesion synthesis (31). Knockdown of USP1 increases mutation frequency 
during DNA replication and causes increased levels of ubPCNA (29). USP1 is activated 
through interaction with USP1 associated factor 1 (UAF1). UAF1 stabilizes USP1 and is 
essential for its deubiquitinating activity. UAF1 is also part of the Fanconi Anemia pathway 
in charge of FANCD2 deubiquitination (30). USP1 alone has very low enzymatic activity, 
however when it is part of a complex with UAF1, its activity increases 35-fold. This 
increase is due to an 18-fold increase in catalytic turnover, and 2-fold increase in the 
  
10 
proteins affinity to its substrate (31). The UAF1-USP1 DUB complex is likely recruited to 
ubiquitinated PCNA through its interaction with ATAD5 (32).  
 UAF1 has an N-terminal WD40 domain containing eight WD40 propeller 
sequences and two consecutive SUMO-like domains (SLD1 and SLD2) in its C-terminal 
(Figure 4). The N-terminal binds and stimulates USP1’s ubiquitin protease activity (33). 
Of the two SLDs in the C-terminal of UAF1, only the second SLD interacts with a SUMO-
interacting motif (SIM) on ATAD5. 
 
1.4 ATPase family, AAA domain-containing protein 5 (ATAD5) 
 ATPase family, AAA domain-containing protein 5 (ATAD5) is the human 
homolog of the yeast protein enhanced levels of genomic stability 1 (Elg1). Elg1 is divided 
into three main domains: an extended N-terminal domain, a central AAA+ ATPase domain, 
and a C-terminal domain (Figure 4) (34). Elg1 was originally identified in a screen for 
suppressors of chromosomal instability and is a protein which participates in telomere 
maintenance in yeast (35, 36). Elg1 has also been suggested to form an RFC-like complex, 
which functions in stabilization of the DNA replication fork. This RFC-like complex 
unloads PCNA from DNA following Okazaki fragment ligation in DNA lagging strand 
synthesis (37, 38). Knockdown of ATAD5 in mammalian cells leads to spontaneous 
chromosomal breaks, increased levels of recombination and aberrations in the chromosome 
such chromosomal fusions and inversions (39, 40).  
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Figure 4. Schematic of ATAD5 and UAF1. A) Schematic diagram of ATAD5 with PCNA-
interacting Protein (PIP) Box and sumo-interacting protein motif (SIM) coloured green and 
yellow respectively. B) Schematic diagram of UAF1 with WD domains coloured orange 
and sumo-like domains coloured blue. 
A 
B 
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Knockdown of ATAD5 also causes PCNA and ubPCNA accumulate on DNA (41). 
Consequently, the lifespan of replication factories (that use PCNA as a scaffold) is 
extended, and remains well into G2 phase of cell division (41). The increase in PCNA 
suggests that ATAD5 may interact with the core subunits of the RFC (rfc2-5) to form an 
RFC-like complex, which is responsible for unloading PCNA similar to its yeast 
homologue (41). Any binding of ATAD5 to PCNA has yet to be investigated, however, a 
non-canonical PIP box motif has been shown to interact with PCNA in yeast (26, 34). The 
accumulation of ubPCNA on DNA is due to ATAD5’s role in recruiting the UAF1-USP1 
DUB complex.  
 ATAD5 interacts with UAF1 through a interaction similar to how the small 
ubiquitin-like molecule (SUMO) interacts with a SIM: a SIM located in the N-terminal of 
ATAD5 interacts with a SUMO-like domain (SLD) of UAF1 (32). The SIM consists of a 
hydrophobic core, consisting of 3-4 aliphatic residues, juxtaposed to a negatively charged 
cluster of acidic residues (42). The binding site of ATAD5 (KSNVVIQEEELELAVLE) 
conforms to the consensus sequence of a SIM, and it is highly conserved among species 
(43). 
 We have previously identified a putative PIP box motif in our lab in the N-terminal 
of ATAD5 (Figure 2). Work done by Haley McConkey showed that a short peptide 
containing this putative motif fused to GST was able to interact with PCNA in an affinity 
pull-down assay. Furthermore, she showed that mutations to the two hydrophobic residues 
at position 7 and 8 of this motif abolished the binding. 
 
 
  
13 
1.5 Scope of thesis 
 Although it is proposed that ATAD5 functions to unload PCNA and recruit the 
UAF1-USP1 DUB complex to ubPCNA, little is known about the interaction between 
ATAD5 and PCNA. In yeast, Elg1 binds to PCNA through a non-canonical PIP box similar 
to that of rfc1, a subunit of the RFC complex. PCNA has many binding partners, and 
regulation of which protein binds at a given time is essential for certain cellular processes 
such as the post replication repair or DDT pathways and DNA replication to occur. 
Elucidation of the structural basis in which ATAD5 binds to PCNA and UAF1 can then be 
applied to other proteins that bind to it.  
The goal of this study is to elucidate the physical and functional relationships 
between the binding of the human proteins: ATAD5, PCNA and UAF1, through structural 
and biochemical methods. The ultimate objective of this study is to contribute  
to our understanding of how the cell is able to recruit Y-family polymerases to stalled 
replication forks arising from DNA lesions and facilitate switching from high- to low- and 
back to high-fidelity polymerases. 
 
1.6 Hypothesis 
As seen in the sequence alignment of ATAD5’s PIP box with other human PCNA-
binding proteins, ATAD5 contains a putative PIP box motif close to its N-terminal that 
resembles those of the Y-family polymerases and rfc1 (Figure 2). Furthermore, ATAD5 
contains a SIM-like motif that interacts with a SLD on UAF1. Therefore, we propose that 
ATAD5 serves as an adaptor protein (Figure 5) that is able to bind both PCNA and UAF1. 
We aim to characterize the physical interaction between the PIP box and SIM motif on the 
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N-terminal of ATAD5 with PCNA and UAF1 through various biochemical methods. 
Finally, we aim to elucidate the structural features of the binding between these proteins 
through macromolecular crystallographic techniques. 
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Figure 5. Schematic diagram of ATAD5 acting as an adaptor protein between 
monoubiquitinated human PCNA and the UAF1-USP1 DUB complex. ATAD5 contains a 
sumo-interacting motif (SIM) that interacts with the second sumo-like domain (SLD2) on 
UAF1 as well as a PCNA-interacting protein motif (PIP box) that interacts with PCNA.  
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CHAPTER 2: MATERIALS AND METHODS 
2.1.1 Bacterial strains and plasmids 
The plasmid expressing full-length wild-type PCNA was previously subcloned 
from pAVR38, a generous gift from Dr. Roger Woodgate of the National Institutes of 
Health (Maryland, USA), into pET22b. The pMCSG9, pMCSG10, pBluescriptR_UAF1 
and pANT7-cGST-ATAD5 plasmids were purchased from the PlasmID Repository 
(Harvard Medical School, Massachusetts, USA). Bacterial strain BL21(DE3) was 
commercially purchased from Novagen. The maps of the vectors used are available in the 
appendix (Figure I-II). A schematic diagram of the various domains from ATAD5 and 
UAF1 used in this study are depicted in Figure 4. 
 
2.1.2 Yeast strains and plasmids 
The PJ694A yeast strain, and pASI and pACT2 vectors were generously provided 
by Dr. Chris Brandl of the Schulich School of Medicine and Dentistry (Western University, 
Ontario, Canada).  
 
2.1.3 List of buffers 
Buffers used in the purification of proteins and experiments have been compiled in 
Table 1. 
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Table 1. Summary of buffers used in this study.*  
Buffer Used In Components 
Buffer A PCNA purification 25 mM Tris pH 7.5, 1 mM EDTA, 7 mM β-Me, 0.01 % NP-40 
Buffer B PCNA purification 25 mM Tris pH 7.5, 1 mM EDTA, 7 mM β-Me, 0.01 % NP-40, 1 M NaCl 
Buffer C PCNA purification 50 mM NaAc pH 5.5, 10 % glycerol, 7 mM β-Me, 0.01 % NP-40 
Buffer D PCNA purification 50 mM NaAc pH 5.5, 10 % glycerol, 7 mM β-Me, 0.01 % NP-40, 1 M NaCl 
Buffer E PCNA purification 25 mM KH2PO4/K2HPO4 pH 7.0, 10 % glycerol, 1 mM DTT 
Buffer F PCNA purification 300 mM KH2PO4/K2HPO4 pH 7.0, 10 % glycerol, 1 mM DTT 
Buffer G PCNA purification 25 mM Tris pH 7.5, 150 mM NaCl, 10 % Glycerol, 1 mM EDTA, 1 mM DTT 
ITC Buffer ITC 25 mM HEPES pH 7.5, 150 mM NaCl, 5 mM β-Me 
HIS Buffer A MBP/GST-tagged 
Protein purification 
25 mM Tris pH 7.5, 500 mM NaCl, 1 mM EDTA, 7 mM β-Me 
HIS Buffer B MBP/GST-tagged 
protein purification 
25 mM Tris pH 7.5, 500 mM NaCl, 1 mM EDTA, 7 mM β-Me, 300 mM imidazole 
Q Buffer A MBP/GST-tagged 
Protein purification 
25 mM Tris pH 7.5, 1 mM EDTA, 7 mM β-Me 
Q Buffer B MBP/GST-tagged 
Protein purification 
25 mM Tris pH 7.5, 1 M NaCl, 1 mM EDTA, 7 mM β-Me 
Pull-Down Buffer Pull-down assays 25 mM HEPES pH 7.5, 150 mM NaCl, 1 mM EDTA, 5 mM β-Me 
GST Elution Buffer GST Purification 25 mM Tris pH 7.5, 200 mM NaCl, 1 mM EDTA, 7 mM β-Me, 10 mM reduced 
glutathione 
MBP Elution Buffer MBP Purification 25 mM Tris pH 7.5, 200 mM NaCl, 1 mM EDTA, 7 mM β-Me, 10 mM maltose 
 
*The referred name is listed under the “Buffer” heading, with the corresponding experiment and components in the columns on the 
right.
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2.1.4 Cloning of constructs used in yeast two-hybrid assay 
 Plasmids pASI-PCNA, pASI-UAF1_SLD2, pACT2-ATAD5_N250, pACT2-
ATAD5_N498 were made through traditional “cut and paste” cloning. Appropriate gene 
segments were amplified with an addition of an appropriate restriction enzyme cut site by 
PCR using the appropriate forward and reverse primers summarized in Table 2.  The 
cloning of these constructs followed a previously described protocol with minor 
modifications (44).  
In brief, the amplification was carried out with 1 ng of DNA template, 500 pM of 
forward and reverse primer, 200 μM of dNTPs, and 1 U of i-MAXTM II DNA polymerase 
(iNtRON) in 20 μL reactions. An initial touchdown protocol was applied to avoid non-
specific binding of the primer, followed by cycling conditions outlined by the 
manufacturer. The annealing temperature for the PCR products varied depending on the 
primers used (Table 2). The PCR products were then diluted and digested with BamHI and 
XhoI along with the vectors (pASI and pACT2) for 2 hours at 37 oC. The digested DNA 
was then purified from a 1.5 % agarose gel using the QIAquick® Gel Extraction Kit 
(Qiagen Inc.). The DNA was then ligated into the appropriate vectors with T4 DNA ligase 
(New England Biolabs Inc.) in a 3:1 molar ratio of insert to vector DNA. 5 μL of the 
ligation reaction was transformed into competent DH5α cells and grown overnight at 37 
oC on LB agar plates supplemented with 100 μg/mL of ampicillin. The plasmids were then 
harvested from 3 mL cultures grown from single colonies and confirmed by DNA 
sequencing.  
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Table 2. Summary of constructs used for yeast two-hybrid experiments..*  
 
Construct  
Protein 
(Mutation) 
Amino Acid 
Residues 
TAnnealing (oC) Primers (Forward and Reverse) 
pASI-PCNA PCNA  64 
5’- taatggatccatatgttcgaggcgcgcctg -3’ 
5’- gctagttattgctcagcgg -3’ 
pASI-UAF1_SLD2 UAF1  559-677 56 
5’- ctgtacttccaatccatgcccaaattcaacaaaattcc -3’ 
5’- ttatccacttccaatttacgtggacttctgacggtaatg -3’ 
pASI-UAF1_SLD2M UAF1 (K595E) 559-677 63 
5’- ctccaagtccgagaagttatggaacatgtttatg -3’ 
5’- gttccataacttctcggacttggagcatgt -3’ 
pACT2-ATAD5_N250 ATAD5  2-250 55 
5’- taatggatccatgtgggggtcctggccatg -3’ 
5’- ctgcatctcgagttaatctctagagtttgcatggc -3’ 
pACT2-ATAD5_N250M 
ATAD5 (I62A, 
Y65A, and F66A) 
2-250 67 
5’- gcactggatgcagcaagaaagacttcacccacaaatgagaag -3’ 
5’- tgctgcatccagtgcattactaggttttggtggagcaaaaacc -3’ 
pACT2-ATAD5_N498 ATAD5 (2-498) 2-498 55 
5’- taatggatccatgtgggggtcctggccatg -3’ 
5’- ctgcatctcgagttatccctctctgtttttgcc -3’ 
pACT2-ATAD5_SIM ATAD5  340-406 56 
5’- taatggatcctaccccgaattttcttgaaacaaaagc -3’ 
5’- ctgcatctcgagttatgctttcataaattgctgtctttc -3’ 
 
*Original protein as well as length of expressed protein are described. Annealing temperatures and primers used are listed. Mutations 
are described in brackets and primers used for mutagenesis.
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 After confirming that the products are correct, mutations to pASI-UAF1_SLD2 and 
pACT2-ATAD5_N250 were introduced to make pASI-UAF1_SLD2M and pACT2-
ATAD5_N250M. The mutagenesis of these two primers was completed using overlap 
extension PCR as previously described with minor modifications (45). The primers were 
designed according to the mutagenic primer-incomplete polymerase extension (M-PIPE) 
protocol (shown in Table 2 with the mutations underlined) (46).  
Briefly, two reactions were set up for each mutation as previously described, 
however one reaction contained the forward primer for the insert and the reverse primer 
for mutagenesis, and the other reaction containing the opposite primer pairs. The two 
reactions were then digested with DpnI for 2 hours at 37 oC to break down the methylated 
template DNA. The two reactions were then purified from a 1.5 % agarose gel using the 
QIAquick® Gel Extraction Kit (Qiagen Inc.) and combined to be used as the template for 
the second PCR step. The same forward and reverse primers for insert amplification were 
used in the second PCR. The products were then digested with BamHI and XhoI and ligated 
into the appropriate vectors as previously described. Following transformation of the 
plasmids into competent DH5α cells, plasmids were extracted from 3 mL overnight 
cultures grown from single colonies. The plasmids were verified using DNA sequencing. 
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 The GST-fusion constructs pMCSG10-ATAD5_PIP, pMCSG10-ATAD5_PIPM 
and pMCSG10-p21 were previously prepared by Guangxing Xing. The GST-fusion 
construct pMCSG10-ATAD5_SIM and the MBP-fusion pMCSG9-UAF1_SLD2 were 
prepared using primer incomplete polymerase extension (PIPE) cloning as previously 
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described with modifications (46). All constructs used for protein expression are listed in 
Table 3 along with the appropriate primers used (where available).  
 In brief, the insert for each construct was amplified using PCR with primers adding 
sequences at the 5’ and 3’ ends complementary to the sequences added to the vectors. The 
vector was also amplified as well. The amplifications were carried out with 1ng of template 
DNA, 500 pM of forward and reverse primers, 200 μM of dNTPs, and 0.5 U of Q5 High-
Fidelity DNA Polymerase (New England Biolabs Inc.). The Q5 High GC Enhancer (New 
England Biolabs Inc.) was added to the reactions to amplify the insert from pANT7-cGST-
ATAD5.  Touchdown PCR was used to amplify the products with an annealing temperature 
range from 65 oC to 55 oC. The products were then digested with DpnI for 2 hours at 37 oC 
and only the vector was purified from a 0.7 % agarose gel using the QIAquick® Gel 
Extraction Kit (Qiagen Inc.). The inserts were then mixed with the vectors and incubated 
at room temperature for 5 minutes and on ice for 5 minutes. 5 uL of this mixture was then 
transformed into competent DH5α cells and grown overnight at 37 oC. 3 mL cultures were 
grown from single colonies and the plasmids were harvested and verified by DNA 
sequencing.  
The same mutation was made to UAF1’s SLD2 domain in pMCSG9-UAF1_SLD2 
as in pASI-UAF1_SLD2 using overlap extension PCR as previously described to create 
pMCSG9-UAF1_SLD2M.  
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Table 3. Summary of constructs used for protein expression and purification. 
 
 
*Original protein as well as length of expressed protein are described. Annealing temperatures and primers used are listed where 
available. Mutations are described in brackets and primers used for mutagenesis.  
Construct  
Protein 
(Mutation) 
Amino Acid 
Residues 
TAnnealing (oC) Primers (Forward and Reverse) 
pMCSG10-p21 p21     -   
pMCSG10-ATAD5_PIP ATAD5 51-75   
pMCSG10-ATAD5_PIPM 
ATAD5 (Y65A and 
F66A) 
51-75  
 
pMCSG10-ATAD5_SIM ATAD5 340-406 55 
5’- ctgtacttccaatcctctgatcctgagaatgaacag -3’ 
5’- ttatccacttccaatttaccaggtttcacagcttcag -3’ 
pMCSG9-UAF1_SLD2 UAF1 559-677 56 
5’- ctgtacttccaatccatgcccaaattcaacaaaattcc -3’ 
5’- ttatccacttccaatttacgtggacttctgacggtaatg -3’ 
pMCSG9-UAF1_SLD2M UAF1 (K595E) 559-677 63 
5’- ctccaagtccgagaagttatggaacatgtttatg -3’ 
5’- gttccataacttctcggacttggagcatgt -3’ 
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2.2 Expression and purification 
2.2.1 Expression and purification of PCNA 
 BL21(DE3) E. coli cells containing the pRARE plasmid were transformed with 
pET22b-hPCNA and incubated at 37 oC overnight. Colonies were picked and grown in a 
50 mL starter culture of 2xYT media containing 100 μg/mL ampicillin and 25 μg/mL 
chloramphenicol. The starter culture was used to inoculate 1 L of 2xYT media with the 
same concentration of antibiotics, supplemented with 6 mM MgCl2. The cultures were 
grown to an OD600 of 1.2 at 37
 oC before induction with 0.5 mM isopropyl-1-thio-β-D-
galactopyranoside (IPTG) for 16 h at 30 oC. Cells were harvested by centrifugation at 4,500 
g and the resulting cell paste was stored at -20 oC until further use.  
Frozen cells were thawed on ice and resuspended in Buffer A (25 mM Tris pH 7.5, 
1 mM EDTA, 7 mM β-Me, 0.01 % NP-40) containing 100 mM NaCl and 1 mM of the 
protease inhibitor, phenylmethylsulfonyl fluoride (PMSF). The cell suspension was lysed 
by three passages through a French press at 15,000 psi. The lysate was then clarified by 
centrifugation at 20,000 rpm  at 4 oC for 30 min. PCNA was then purified to near 
homogeneity as previously described, with modifications (47). 
 In brief, the supernatant was loaded onto two 5 mL HiTrap Q HP columns (GE 
Healthcare Life Sciences) pre-equilibrated with Buffer A containing 10 % Buffer B (25 
mM Tris pH 7.5, 1 mM EDTA, 7 mM β-Me, 0.01 % NP-40, 1 M NaCl) for anion exchange 
chromatography. The protein was eluted off of the columns using a gradient of Buffer B. 
Fractions containing PCNA were pooled and diluted with Buffer C (50 mM NaAc pH 5.5, 
10 % glycerol, 7 mM β-Me, 0.01 % NP-40) until the approximate NaCl concentration was 
50 mM. This sample was applied to two 5 mL HiTrap Heparin HP columns and eluted with 
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a gradient of Buffer D (50 mM NaAc pH 5.5, 10 % glycerol, 7 mM β-Me, 0.01 % NP-40, 
1 M NaCl). The fractions containing the protein was pooled and dialyzed against Buffer E 
(25 mM KH2PO4/K2HPO4 pH 7.0, 10 % glycerol, 1 mM DTT) overnight. The sample was 
then loaded onto a packed 12 mL CHT ceramic hydroxyapatite Type I column. The protein 
was eluted off of the column using a gradient of Buffer F (300 mM KH2PO4/K2HPO4 pH 
7.0, 10 % glycerol, 1 mM DTT). Fractions containing the protein of interest were pooled 
and concentrated and subjected to size exclusion chromatography on a SuperdexS200 
10/300 GL equilibrated with Buffer G (25 mM Tris pH 7.5, 150 mM NaCl, 10 % Glycerol, 
1 mM EDTA, 1 mM DTT).  
 
2.2.2 Expression and purification of recombinant proteins 
All plasmids constructed with the pMCSG9 and pMCSG10 vectors (Table 3) were 
transformed into competent E. coli BL21(DE3) cells following standard protocols (48). 
The same procedure was applied to all of the plasmids.  
Single colonies were picked following transformation and grown as 5 mL cultures 
overnight in LB media overnight supplemented with 100 μg/mL of ampicillin. These 
cultures were then added to 1 L of the same media and grown to an OD600 of 0.8 at 37 
oC 
before being induced with 0.5 mM of IPTG for 16 hours at 16 oC. Cells were harvested by 
centrifugation at 4,500 g and the resulting cell paste was stored at -20 oC until required for 
further use.  
The frozen cell paste was thawed on ice and the cells were resuspended in HIS 
Buffer A (25 mM Tris pH 7.5, 500 mM NaCl, 1 mM EDTA, 7 mM β-Me) spiked with 
1mM of the protease inhibitor, PMSF. The cell suspension was lysed by two passages 
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through an Emulsiflex cell homogenizer (Avestin) at 15,000 psi. The lysate was then 
clarified by centrifugation at 20,000 rpm at 4 oC for 30 min.  
 
2.2.3 Purification of GST-p21, GST-ATAD5_PIP, GST-ATAD5_PIPM, and GST-
ATAD_SIM 
Recombinant proteins were purified by immobilized metal affinity chromatography 
(IMAC) followed by anion exchange chromatography following the manufacturer’s 
suggested protocols. Briefly, clarified lysate was loaded onto two 5 mL prepacked 
cOmplete His-tag purification columns (Roche) pre-equilibrated with HIS Buffer A and 
washed with HIS Buffer A + 10 mM imidazole. Proteins were then eluted using HIS Buffer 
B (25 mM Tris pH 7.5, 500 mM NaCl, 300 mM imidazole, 1 mM EDTA, 7 mM β-Me). 
The eluents were diluted with Q Buffer A (25 mM Tris pH 7.5, 1 mM EDTA, 7 mM β-Me) 
until the approximate NaCl concentration was 50mM and applied to two 5mL HiTrap Q 
HP columns equilibrated with 5% Q Buffer B (25 mM Tris pH 7.5, 1 mM EDTA, 7 mM 
β-Me, 1 M NaCl) and eluted with a gradient of Q Buffer B. The proteins were then 
concentrated using centrifugation using Vivaspin 6 ultrafiltration devices with appropriate 
molecular weight cut offs. The concentrated proteins were stored at -20 oC after spiking 
the samples with glycerol to 50 %. 
 
2.2.4 Purification of GST, UAF1_SLD2, UAF1_SLD2M, and ATAD5_SIM 
The purification of GST, UAF1_SLD2, UAF1_SLD2M, and ATAD5_SIM 
proteins followed the above protocol with slight modifications. After IMAC, His-tagged 
TEV protease was added to GST-ATAD5_SIM, MBP-UAF1_SLD2, and MBP-
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UAF1_SLD2M at a 1:20 ratio and dialyzed against 5% Q Buffer B overnight to cleave the 
GST and MBP tags. Each of the resulting samples were passed through two 5 mL 
prepacked cOmplete His-tag purification columns (Roche) pre-equilibrated with HIS 
Buffer A, removing the TEV protease and the His-tagged tags from the flow through. The 
flow through fraction containing the cleaved protein was then diluted with Q Buffer A to a 
NaCl concentration of approximately 50 mM and anion exchange chromatography was 
performed as described above.  
The remaining protein on the IMAC column was eluted with HIS Buffer B and 
these fractions were applied to the appropriate prepacked columns (either MBPTrap HP 
columns or GSTrap HP columns (GE Healthcare)) equilibrated with HIS Buffer A to 
remove TEV Protease. Proteins were eluted with the appropriate buffers (GST Elution 
Buffer (25 mM Tris pH 7.5, 200 mM NaCl, 1 mM EDTA, 7 mM β-Me, 10 mM reduced 
glutathione) or MBP Elution Buffer (25 mM Tris pH 7.5, 200 mM NaCl, 1 mM EDTA, 7 
mM β-Me, 10 mM maltose)). The buffer was exchanged and the proteins were concentrated 
using centrifugation using Vivaspin 6 ultrafiltration devices with appropriate molecular 
weight cut offs. The concentrated proteins were stored at -20 oC after glycerol was added 
to a final concentration of 50 %.  
 
2.3 Affinity pull-down 
GST pull-down and His-affinity pull-downs were carried out using similar 
protocols. 50 μg of GST-tagged protein (bait) was immobilized onto glutathione sepharose 
resin equilibrated in Pull-Down Buffer (25 mM HEPES pH 7.5, 150 mM NaCl, 1 mM 
EDTA, 5 mM β-Me). After 1 hour on ice with gentle agitation, the beads were spun down 
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by centrifugation (1 minute at 600 g) and the supernatant was removed.  The beads were 
then washed with Pull-Down Buffer to remove excess protein. Prey proteins were then 
added in excess and allowed to incubate with the immobilized bait for 1 hour on ice with 
occasional agitation. Unbound protein was then removed through three washes. Each wash 
involved adding 200 μL of Pull-down buffer, agitating the mixture, spinning down the 
resin, and removing the supernatant. Finally, bound proteins were stripped from the resin 
by adding 50 μL of 1x SDS-PAGE loading buffer and boiled for 5 minutes. The samples 
were then subjected to analysis by SDS-PAGE. The proteins were visualized by Coomassie 
Brilliant Blue staining.  
 
2.4 Isothermal titration calorimetry 
A synthetic 18 amino acid peptide containing ATAD5’s PIP box was purchased 
from and purified by the Tufts University Protein Core Faculty (Boston, USA). The 
sequence of the peptide was: APPLPSNILDYFRKTSPT. The peptide was then dissolved 
in ITC buffer (25 mM HEPES pH 7.5, 150 mM NaCl, 5 mM β-Me). The proteins were 
thoroughly dialyzed and degassed under vacuum before the experiments were conducted. 
Isothermal titration calorimetry (ITC) measurements were either performed on the VP-ITC 
calorimeter (GE Healthcare) or the Nano ITC calorimeter (TA Instruments) at 25 oC. The 
titration of the peptide into PCNA was performed using the VP-ITC calorimeter. The 
peptide (750 μM) was loaded into the syringe and injected into the cell containing 50 μM 
PCNA in 60 injections of 5μL. A control experiment was performed by injecting the 
peptide into buffer under the same experimental conditions. Experimental traces were 
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corrected by subtracting the control measurements, and analyzed using Origin 7 
(MicroCal). Binding constants, ΔG, and ΔH were calculated 
The titrations of ATAD5_SIM into UAF1_SLD2 and UAF1_SLD2M were 
performed using the Nano ITC calorimeter. ATAD5_SIM (1 mM) was titrated into a cell 
containing 100 μM of UAF1_SLD2 in 25 2 μL injections following an initial 0.5 μL 
injection. Control experiments were performed by injecting the peptide into buffer under 
the same experimental conditions. Experimental traces were corrected by subtracting the 
control measurements, and analyzed using NanoAnalyze (TA Instruments). Binding 
constants, ΔG, and ΔH were calculated by fitting the integrated titration data to an 
independent binding model.   
 
2.4 Yeast two-hybrid assays 
The yeast strain used was PJ69-4A and has the genotypes as described (49). Human 
PCNA was recombinantly expressed with the binding domain of the GAL4 by the 
integrative vector pASI. Native and mutant N-terminal ATAD5 containing the PIP-box 
was recombinantly expressed with the activating domain of GAL4 using the pACT2 vector. 
Yeast cells were sequentially transformed using the LiAc method (50) with the bait plasmid 
and then the prey plasmid. Selection of the cells containing both the bait and prey plasmids 
was carried out on media lacking tryptophan and leucine. Positive interactions were scored 
by growth on medium lacking histidine or histidine and adenine.  
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2.5 Crystallization 
2.5.1 Crystal screening and optimization 
Proteins used for crystallization condition screening were either freshly purified or 
subjected to size exclusion chromatography. Flash-frozen protein stored at -80 oC was 
thawed and loaded onto a SuperdexS200 10/300 GL equilibrated with ITC Buffer. Eluted 
protein was then diluted or concentrated for use in crystallization experiments. 
 Protein complexes were made prior to setting up crystallization trials. PCNA at a 
concentration of 1 mg/ml was mixed with 2 molar excess of the synthetic peptide derived 
from ATAD5 used in ITC experiments. The protein solution was then left to incubate for 
1 hour at room temperature before being concentrated to 6 mg/mL. The ATAD_SIM-
UAF1_SLD2 complex was collected after ITC experiments were performed and was 
concentrated to a concentration of 9 mg/mL. The approximate ratio of ATAD5_SIM to 
UAF1_SLD2 is 3:1. 
Crystal screening was carried out using both the hanging drop and sitting drop 
vapour diffusion method with various commercially available and in-house crystallization 
kits. The kits used to screen both complexes included: Hampton Research: Crystal Screen 
kit 1, Crystal Screen kit 2, Natrix, and PEG/Ion Kit and Wizard Classic Crystallization 
Screen Kit 1, 2, 3, and 4. In addition to the kits mentioned, the peptide-PCNA complex 
was also screened with: JSGC+ Crystal Screen, Molecular Dimensions: Midas Crystal 
Screen Kit and in-house PEG/Ion screens with varying PEG molecular weights. 1 μL of 
protein complex was mixed with 1 μL of the well solution and incubated over a reservoir 
of the same well solution.  
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After hits were observed, optimization of crystallization conditions was carried out. 
Crystals were grown at varying precipitant concentrations and microseeding was employed 
in order to improve the shape of crystals. A seed solution was prepared by bead-beating 
harvested crystals suspended in mother liquor and added to fresh drops. Additives were 
also screened using Hampton Research: Optimization Screen Kit, following the 
manufacturer’s suggested protocol. 
 
2.5.2 Data collection and refinement 
Crystals were initially screened at the home-source to identify highly diffracting 
crystals for data collection. Several crystals were frozen in liquid nitrogen during the 
screening process. Highly diffracting crystals were sent to the Canadian Light Source 
(Saskatchewan, Canada) for data collection at the CMCF-081D beam line. 
The crystal structure was solved using iMOSFLM (51) and the CCP4 program suite 
(52). The reflection images were integrated using iMOSFLM and scaled using SCALA and 
CTRUNCATE (53, 54). Initial phases were obtained by molecular replacement using 
3VKK as a search model in PHASER (55). An initial rigid body refinement was carried 
out by RefMac (56) followed by successive rounds of structure building with COOT (57) 
and restrained refinements using RefMac. Non-crystallographic symmetry was applied 
throughout the refinement process. 
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CHAPTER 3: RESULTS I INTERACTION BETWEEN ATAD5 AND PCNA 
3.1 Cloning of plasmids  
A variety of plasmids were generated in this study to assess the interactions between 
ATAD5, PCNA, and UAF1. A summary of the plasmids used and generated is presented 
in Tables 2 and 3. All of the plasmids used were confirmed to be correct using DNA 
sequencing.  
Subcloning was used to generate the plasmids for the yeast two-hybrid studies. 
Insert DNA was amplified by PCR and digested with the appropriate restriction 
endonucleases and ligated into either pASI or pACT2. The pASI and pACT2 vectors 
encode for fusion proteins between the protein of interest and the binding domain and 
activating domain of Gal4 respectively.  
PIPE cloning was used to generate the plasmids for expression and purification of 
ATAD5’s SIM and UAF1’s second SLD (SLD2). The primers used to amplify the insert 
(by PCR) added a sequence of nucleotides on each end, complementary to the ends on the 
vector. This technique uses the cell’s DNA repair machinery to ligate the plasmid. The 
plasmids pMCSG9 and pMCSG10 encode the protein of interest fused to the C-terminal 
of MBP and GST respectfully. MBP and GST are both tagged with an N-terminal poly-
His tag and contain a TEV cut site at the C-terminal.   
The mutation made to the plasmids containing ATAD’s PIP box motif and UAF1’s 
SLD2 was achieved by overlap extension PCR. The key PIP box motifs of ATAD5 (I62, 
Y65 and F66) were all mutated to Ala using the primers indicated in Table 2. Yang et al. 
(2011) reported that a K595E mutation in UAF1 would significantly reduce the ability of 
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UAF1 to bind to ATAD5, so this mutation was also used in this study using the primers 
indicated in Table 3 (43). 
 
3.2 Purification of proteins 
3.2.1 Purification of PCNA  
Human PCNA was expressed in E. coli and purified to near homogeneity (Figure 
6). Following cell lysis, the sample was clarified using high-speed centrifugation for 15 
min at 7000 g. The supernatant was then applied onto prepacked HiTrap Q columns for 
anion exchange chromatography (Figure 6A). The protein was eluted from the column 
using an increasing gradient of ionic strength. The protein was further purified by heparin 
affinity chromatography (Figure 6B). The fractions containing PCNA from anion exchange 
chromatography was diluted to reduce the concentration of NaCl before being loaded onto 
HiTrap Heparin columns. The protein was again eluted from the column using a gradient 
of increasing ionic strength. PCNA was still not sufficiently pure, so the sample was 
subjected to mix mode chromatography via ceramic hydroxyapatite (Figure 6C). 
Hydroxyapatite chromatography has unique separation properties and can sometimes 
separate proteins shown as homogeneous by other chromatographic or electrophoretic 
techniques (58). The sample was applied to a 12 mL column and eluted using an increasing 
gradient of potassium phosphate. The final low molecular weight contaminants were 
removed by size exclusion chromatography (Figure 6D), as PCNA is significantly larger 
in solution (as a trimer). Typically, 5 grams of cell paste yielded 25mg of protein. SDS-
PAGE analysis shows that this protein is suitable for biochemical and structural studies.   
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Figure 6. Purification of human proliferating cell nuclear antigen (PCNA) (28.7 kDa). 
SDS-PAGE analysis after each stage of chromatography. Blue arrows indicate the band of 
interest. A) Anion exchange chromatography using HiTrap Q columns. Cell lysate, soluble 
protein, flow-through, and eluted fractions are indicated. Fractions in blue box were 
pooled. B) Eluted fractions from Heparin affinity chromatography. Fractions 4-6 were 
pooled. C) Eluted fractions from hydroxyapatite chromatography. D) Peak fraction of 
PCNA after size exclusion chromatography. PCNA is near homogeneity. 
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Despite having a predicted molecular weight of 28.7 kDa, individual PCNA 
monomers runs at about 34-35 kDa on a 15% SDS-PAGE gel. Gulbis et al. 1996 had 
previously reported that human PCNA runs at a higher apparent molecular weight (47). 
PCNA from other organisms such as Schizoscaccharomyces pombe and tomatoes have also 
been reported to run higher than their expected molecular weight (59, 60). 
 
3.2.2 Purification of GST-fusion proteins 
The GST-fusion proteins (GST-p21, GST-ATAD5_PIP and GST-ATAD5_PIPM) 
were expressed in E. coli following the same growth and induction parameters. The vector 
(pMCSG10) that encodes the recombinant proteins includes a poly-his tag in the N terminal 
of GST, allowing IMAC to be utilized as the first purification step. Figure 7A shows a 
representative purification of GST-ATAD5_PIPM.  
The proteins were purified to near homogeneity after IMAC and anion exchange 
chromatography. All of the proteins were soluble following cell lysis. Clarified lysate was 
loaded onto 5 mL prepacked cOmplete His-tag purification columns (Roche). After a wash 
with a low concentration of imidazole, the remaining proteins were eluted using a high 
concentration of imidazole.  The eluted sample was then diluted to reduce the NaCl 
concentration and loaded onto HiTrap Q HP columns (GE Healthcare) for anion exchange 
chromatography. The protein was then eluted using an increasing gradient of ionic strength. 
Typically, 10 mg of protein was obtained from 0.5 L cultures.  
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Figure 7. Purification of GST-fusion proteins. Purification of ATAD5_PIPM as a 
representative purification of GST-fusion proteins. A) SDS-PAGE analysis of the cell 
lysate and soluble fraction. The sample was applied to two cOmplete His-tag purification 
columns, washed with 10mM imidazole and eluted with 300mM imidazole. Following 
IMAC, sample was subjected to anion exchange chromatography via HiTrap Q HP column. 
Protein was eluted using increasing ionic strength. B) SDS-PAGE analysis of all GST and 
GST-fusion proteins used in pulldowns. GST-p21 (30.4 kDa), GST-ATAD5_PIP (31.2 
kDa), and GST-ATAD5_PIPM (31.1 kDa) ran close to their expected molecular weights. 
The apparent molecular weight of GST (28.3 kDa) and PCNA (28.7 kDa) were slightly 
higher than expected.  
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The GST protein to be used as negative controls for the affinity pull-downs were 
purified from the cleavage products of tagged protein with TEV protease. Both the GST 
and TEV protease contained the poly-His tag, so GST affinity chromatography was used 
to separate them. GST and TEV protease was eluted from the IMAC columns after the 
cleaved protein of interest was removed. The sample was directly loaded onto a GSTrap 
HP (GE Healthcare) and eluted with a buffer containing 10 mM of reduced glutathione. 
Typically, 5 mg of GST was obtained from the digestion of 7 mg of GST-p21.  
These proteins were resolved close to their predicted molecular weights during 
SDS-PAGE analysis and are of sufficient quality to be used in biochemical assays (Figure 
7B). GST-p21 (30.4 kDa), GST-ATAD5_PIP (31.2 kDa), and GST-ATAD5_PIPM (31.3 
kDa) ran close to their expected molecular weights. The apparent molecular weight of GST 
(28.3 kDa) was slightly higher than expected. 
 
3.2 GST Pull-down assays 
Work by a previous student showed that the identified putative PIP box in 
ATAD5’s N-terminal was able to bind to PCNA, and that mutation of these residues 
abolished the binding. The GST pull-down assay was replicated to confirm the findings. In 
brief, GST-bound proteins (bait) were incubated with glutathione agarose resin and 
allowed to bind. Unbound protein was then washed off and PCNA (prey) was added to the 
resin in excess. After several rounds of washing, only the protein that interacts with the 
bait remain. These proteins were eluted from the resin and analyzed using SDS-PAGE on 
a 15% polyacrylamide gel (Figure 8).  
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Figure 8. Pull-down assay showing the interaction between ATAD’s PIP box and PCNA. 
Excess GST or GST-fused protein was immobilized onto glutathione resin. Unbound 
protein was then washed off and PCNA (prey) was added to the resin in 2 molar excess. 
After several rounds of washing, bound protein were eluted from the resin and analyzed by 
SDS-PAGE on a 15% polyacrylamide gel. Proteins used in each reaction is shown above 
by a “+”, PCNA is indicated by arrows. 
 
  
  INPUT   OUTPUT  
PCNA + + + + + + + + 
GST + - - - + - - - 
GST-P21 - + - - - + - - 
GST-ATAD5_PIP - - + - - - + - 
GST-ATAD5_PIPM - - - + - - - + 
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PCNA was observed to co-elute with the native ATAD5 PIP box along with the 
positive control using the PIP box from p21. The intensity of the PCNA band was 
significantly lower in the lane containing ATAD5 compared to the lane containing p21. 
This suggests that the interaction between the PIP box of ATAD5 is weaker than that of 
P21 with PCNA. Mutation of the two aromatic residues (Tyr65 and Phe66) to Ala abolishes 
the interaction, as PCNA not present in the eluted proteins (Figure 7). 
From the Pull-down experiment, we can conclude that the putative PIP box from 
ATAD5 interacts with PCNA. Also, this experiment demonstrates that the two aromatic  
residues of this PIP box is important for binding. Therefore, we can infer that the binding 
mode of this PIP box to PCNA is similar to that of canonical PIP boxes.  
 
3.3 Yeast two-hybrid assays 
To confirm the results of the GST pull-down assays, the interaction between the N-
terminal of ATAD5 containing the PIP box with PCNA was analyzed in a yeast two-hybrid 
system. The two-hybrid system takes advantage of a transcriptional activator that has two 
separable functions: one to bind to a specific region of DNA, and the second, to increase 
the frequency with which transcription is initiated on an adjacent gene (Figure 9A) (61). 
The binding domain (BD) and activating domain (AD) of the transcriptional activator Gal4 
is encoded separately by the pASI and pACT2 vectors fused to proteins of interest (62). 
The ability to synthesize Leu and Trp is conferred by pASI and pACT2 respectlvely. The 
yeast stain that is used in this study (PJ69-4A), will express β-galactosidase and be able to 
synthesize His and Ade upon activation of the reporter genes by Gal4 (49).  
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PJ69-4A yeast cells were sequentially transformed with plasmids made from the 
pASI vector and then the pACT2 vector. PJ69-4A cells were initially transformed using 
the LiAc/single-stranded carrier DNA/PEG method with plasmids made with the pASI 
vector and plated on selective media lacking Trp. Colonies were picked for each plasmid 
and then subsequently transformed with plasmids made with the pACT2 vector. Co-
transformed cells were selected by their ability to grow on selective media lacking both 
Trp and Leu.  
Binding of the N-terminal 250 amino acid residues of ATAD5 and PCNA was 
assessed by spot plating co-transformed cells on increasingly selective media. 
Transcription of the reporter genes responsible for His and Ade synthesis will allow the 
cells to survive on media without these amino acid residues. Cells transformed with both 
pASI-PCNA and pACT2-A250 were able to grow on plates lacking Trp, Leu, and His 
and/or Ade (Figure 9B). Cells transformed with both pASI-PCNA and pACT2-
ATAD_N250M (containing mutations to key PIP box residues), were not able to grow on 
the plates lacking His and/or Ade (Figure 9B). From these results, we have confirmed that 
the putative PIP box is able to interact with PCNA and mutations of the conserved residues 
in the PIP box abolishes binding. 
 
3.4 Isothermal titration calorimetry 
 With the interaction between ATAD5’s PIP box and PCNA confirmed by both GST 
pull-down assays and the yeast two-hybrid system, we wanted to characterize the 
interaction. The thermodynamic parameters of the interaction were characterized by ITC 
using the VP-ITC calorimeter. In ITC, the energy absorbed or given off from a reaction  
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Figure 9. Interaction of ATAD5’s N-terminal 250 amino acids with native PCNA in a 
yeast two-hybrid system. A) Binding of the two proteins fused to Gal4’s binding domain 
and activating domain will start transcription of t. B) PJ694A cells were successively 
transformed with the plasmid encoding native human PCNA and then with either the 
pACT2 vector, encoding only the AD of Gal4, and pACT2-ATAD5_N250 or pACT2-
ATAD5_N250M which encodes the N terminal 250 amino acids of ATAD5 or the mutant. 
These cells were then spot plated with an initial dilution of 1000x and then serial diluted 4 
times on increasing selective media (blue triangles represent dilution). 
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between two components is measured and the thermodynamic terms that define the binding 
affinity, enthalpy (∆H) and entropy (∆S), can be determined (63). 
The binding affinity of ATAD5’s PIP box with PCNA was determined using a 
synthetic peptide. The full-length ATAD5 protein is relatively large, comprising of 1844 
amino acid residues, with the first ~1000 residues predicted to be disordered. For this 
reason, an 18 amino acid residue peptide was synthesized that contained the PIP box of 
ATAD5. The flanking sequence of amino acids on both sides of the PIP box were 
conserved. The synthetic peptide containing the PIP box of ATAD5 was diluted in ITC 
buffer and thoroughly dialyzed. The pH of the peptide sample after dialysis overnight did 
not match that of the buffer, so the time of dialysis was extended to 36 hours total. The 
peptide was loaded into the syringe and titrated stepwise into the cell containing PCNA. A 
control experiment was conducted in which the peptide was titrated into a cell containing 
ITC Buffer only (Figure 10A). The control experiment was subtracted from the 
experimental traces and fitted to a one-site binding model (Figure 10B-C). The Kd of the 
interaction was determined to be 6.17  0.78 M with an n of 0.93 ± 0.01. The 
stoichiometry of the reaction is close to 1, meaning that each peptide binds to one 
monomer.  The H, S and G of the reaction is -2.18 ± 0.04 kcal, 16.5 cal mol-1 K-1 and 
-7.01 kcal/mol respectively. 
From the ITC data, we determined that the interaction is in the low micromolar 
range, each monomer of PCNA is able to bind to one peptide, and that the interaction occurs 
under favourable conditions, however it is non-spontaneous. 
 
 
    
43 
 
                                        
 
 
                    
 
Figure 10. Determination of the thermodynamic parameters of the binding between 
ATAD5’s PIP box and PCNA. Thoroughly dialyzed peptide (800μM) was titrated stepwise 
into the cell in 2.5μL injections at 25oC. Binding thermograms from titration of a synthetic 
peptide containing ATAD5’s PIP box into the cell. A) A control experiment was conducted 
in which the peptide was titrated into a cell containing ITC Buffer only. B) The peptide 
was titrated into a cell containing 40μM of PCNA. C) Replicate of titration described in 
(B) 
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3.5 Crystallization of PCNA:ATAD5 peptide complex 
 In order to determine the structural features of the binding between the PIP box of 
ATAD5 and PCNA, the x-ray crystal structure was determined. Since ATAD5 is too large 
for crystallographic experiments, the 18 amino acid residue peptide from ITC experiments 
was used. Crystallization trials were conducted to determine the condition where both 
PCNA and the peptide would co-crystalize. 
 
3.5.1 Screening and optimization 
Crystallization trials were carried out in order to determine the condition required 
to crystalize the protein-peptide complex. PCNA at 1 mg/mL was incubated with the 
peptide dissolved in ITC Buffer in 3 molar excess for 1 hour at room temperature. The 
protein complex was then concentrated to 6 mg/mL. Both the hanging drop and sitting drop 
vapour diffusion techniques were used in the screen. 1 L of the protein complex was 
mixed with 1 L of the well solution and suspended over 500 L resovoir of well solution. 
The well solutions were from commercial and in-house crystallization kits. In the end over 
1000 unique conditions were screened. Many conditions produced crystals, however, they 
closely resembled the native crystallization conditions and were rejected. Other conditions 
that were identified by the screen included: 2 M ammonium sulphate, citrate pH 5.5, 50 % 
PEG 400, 0.1 M sodium acetate/acetic acid pH 4.5, and 30 % PEG 400, 0.2 M calcium 
acetate (Figure 11). The condition using 30 % PEG 400 and 0.2 M calcium acetate was 
reproducible and produced crystals within 2-3 days so it was chosen for optimization. 
Initially, the crystals were not well formed (Figure 11D); however, if PCNA was subjected 
to size exclusion chromatography on a Sephadex S200 10/300 GL  
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Figure 11. Hits from crystallization trials for complex of PCNA and a synthetic peptide 
derived from ATAD5. 1 L of the protein complex was mixed with 1 L of the well 
solution and suspended on 500 L of well solution. The well solutions were from 
commercial and in-house crystallization kits. 3 hits were observed. A) 2 M ammonium 
sulfate, citrate pH 5.5. B) 50% PEG 400, 0.1 M sodium acetate/acetic acid pH 4.5. C) 30% 
PEG 400, 0.2 M calcium acetate. D) Crystallization condition from (C) was reproducible. 
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column equilibrated with 25 mM HEPES pH 7.5, 150 mM NaCl and 5 mM β-Me prior to 
forming the complex, more of the resulting crystals are well-shaped and larger (Figure 
12A). These crystals did not diffract past 6 Å however.   
Both the micro seeding and streak seeding techniques were used in an attempt to 
produce better diffracting crystals. Microseeding appeared to be more effective, however, 
large crystal showers were observed (Figure 12B). Different precipitant concentrations 
were then screened in combination with microseeding. Larger well-shaped crystals were 
observed at 25 % PEG 400 (Figure 12C). Since low molecular weight PEGs are suitable 
cryoprotectants, these crystals were directly frozen in liquid nitrogen to be used in x-ray 
diffraction experiments. Despite lacking any visual imperfections, the crystals only 
diffracted to a maximum of 4.5 Å at the Canadian Light Source. After multiple rounds of 
crystallization without high-diffracting crystals, additives were screened from the 
Optimization Screen Kit (Hampton Research) following the manufacturer’s instructions. 
Many additives produced the same well-shaped crystals, all corresponding to metal cations. 
The largest, well-shaped crystals appeared with the addition of MgCl2. Finally, a crystal of 
the protein complex was grown in 25 % PEG 400, 0.2 M calcium acetate, and 10 mM 
MgCl2 with microseeding (Figure 11D). These crystals diffracted with higher resolution, 
up to 2.2 Å on the CMCF-081D beam line at the Canadian Light Source. 
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Figure 12. Optimization of the crystallization condition for the crystallization of 
PCNA/Peptide complex. The initial condition of 30% PEG 400, 0.2M calcium acetate was 
used. 2 L of the protein complex was mixed with 2 L of the well solution and suspended 
over 500 L of well solution. A) Use of protein refreshed via size exclusion 
chromatography pre-equilibrated in ITC Buffer (25 mM HEPES pH 7.5, 150 mM NaCl, 5 
mM β-Me) produced larger well shaped crystals. B) Protein crystals from A were used to 
make a seed stock for microseeding. 0.2 L of this stock was added to drops. Many small 
well-formed crystals grew. C) Concentration of PEG 400 was reduced to 25 %. This 
produced larger crystals, however none of the crystals diffracted past 4.5 Å. D) Final drop 
was spiked with MgCl2 to a final concentration of 10 mM. Resulting crystals were large 
and diffracted to high resolution.  
A B 
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3.5.2 Structure determination of PCNA:ATAD5 peptide complex 
The highest diffracting dataset was used to solve the structure of the complex 
between PCNA and the synthetic peptide containing ATAD5’s PIP box. First, the 
collection of refraction images was processed in iMOSFLM (51). From previous datasets 
obtained from the home source, the space group was thought to be h6, however, the recent 
high-resolution dataset showed that the space group was either P3121 or P3122. The cell 
parameters were consistent with the previous low-resolution dataset, with two axis of the 
same length (a, b = 83.7 Å) and one significantly longer axis (c = 209.6 Å). Integration of 
the data set was disrupted by refraction images that contained large spots. Removal of these 
images from the dataset allowed for the integration of the remaining dataset into one .mtz 
file. The data was then scaled to a resolution of 2.2 Å with CTRUNCATE and SCALA 
(53). Initial phases were obtained by molecular replacement in PHASER  using monomeric 
human PCNA structure (PDB ID: 3VKX) as a search model (55). Here, the space group 
was determined to be P3121, with three PCNA monomers in the asymmetric unit cell. After 
an initial rigid body refinement in RefMac, successive rounds of structure building in 
COOT and smooth body refinements with non-crystallographic symmetry restraints were 
carried out (56, 57). Un-modeled blobs around the hydrophobic region of PCNA where 
initially filled with Ala before mutation of the residues to correspond with the peptide 
sequence. The data collection and refinement statistics are summarized in Table 4.  
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Table 4. Data collection and refinement statistics for the structure of PCNA with a 
synthetic peptide derived from ATAD5.*  
 
Data collection  
Space group P3121 
Cell dimensions   
    a, b, c (Å) 83.7, 83.7, 209.6 
 ()  90, 90, 120 
Resolution (Å) 50.0-2.20(2.32-2.20) 
Rsym or Rmerge 0.10(0.63) 
I/I 10.9 (3.4) 
Completeness (%) 99.9 (100.0) 
Redundancy 8.5 (8.9) 
  Refinement  
Resolution (Å) 50.0-2.20 
No. reflections 44, 086  
Rwork/ Rfree 22.5/27.6 
No. atoms  
    Protein 5852 
    Peptide 289 
    Mg2+/PEG 2/14 
    Water 228 
B-factors  
    Protein 45.8 
    Peptide 66.1 
    Mg2+/PEG 58.9/47.5 
    Water 45.9 
R.m.s deviations  
    Bond lengths (Å)  0.010 
    Bond angles (º) 1.53 
 
 
*Values in parenthesis are for the highest-resolution shell.  Crystal data was collected on 
the CMCF-081D beam line at the Canadian Light Source (Saskatchewan, ON). The data 
was integrated using iMOSFLM and scaled with SCALA and CTRUNCATE. Molecular 
replacement was performed using PHASER with the search model 3VKX. Successive 
rounds of refinement and model building was done using REFMAC and Coot.    
    
50 
3.5.3 PCNA:ATAD5 peptide complex structure 
The crystal structure was solved by molecular replacement to a resolution of 2.20 
Å. The PCNA structure has three subunits that are arranged head-to-tail (Figure 13C). The 
quaternary structure is of a toroid, as N- and C-terminal regions form subunit-subunit 
contacts. The monomers are structurally similar, with RMSD values between subunits 
ranging from 0.397 to 0.559 Å over 248 residues and surface areas ranging from 12318 to 
12737 Å2. The PCNA trimer has a pseudo 6-fold symmetry, with two similar domains in 
each subunit. Each domain consists of 2 α-helices and 9 β-strands. The trimer therefore 
consists of 12 α-helices and 54 β-strands in total. Each monomer was modelled 
unambiguously from residues 1-256, however there was poor density for the five C-
terminal residues and a loop region in two of the monomers. Similar regions of missing 
density have been reported in other PCNA structures as well (64–66).  
One peptide molecule binds to each of the three PCNA monomers in the 
asymmetric unit. Binding the peptide does require or induce large-scale structural 
rearrangements of PCNA as there is little global change upon peptide binding (Figure 14). 
The peptide-bound PCNA structure is structurally similar to the apo PCNA structure 
(1VYM), with a RMSD of 0.75Å over 248 residues. According to the x-ray structure 
model, 9 to 13 of the 18 amino acids in the peptide were resolved in each subunit.  
The three peptides are also structurally similar, with RMSD values between 0.37 to 
0.51 Å over 66 atoms. The surface areas of the peptide range from 1395 to 1729 Å2 with 
the contact surface area ranging from 562 to 673 Å2 (approximately 40 %). Figure 13D 
shows the electron density (2Fo - Fc) map contoured to 1.2 Å around the peptide with  
respect to PCNA.  
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Figure 13. Structure of PCNA co-crystalized with a synthetic peptide derived from 
ATAD5. A) Crystal mounted onto 0.2-0.3mm loop and directly frozen in liquid nitrogen. 
B) Diffraction image taken of crystal at CMCF-081D beam line at the Canadian Light 
Source. Crystals diffracted to 2.2Å and belonged to the space group P3121 with unit cell 
dimensions of a, b = 83.7 Å and c = 209.6 Å. C) Cartoon representation of complex 
structure with transparent surface. One peptide (yellow) binds to each monomer of PCNA 
(purple). D) 11-13 residues of the peptide were resolved in the final structure. 2Fo - Fc map 
of peptide represented as sticks (yellow) is shown and contoured to 1.2 Å. 
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Figure 14. Binding of peptide does not induce significant conformational changes in 
PCNA. Cartoon representation of the two structures superimposed is shown. The co-crystal 
structure of PCNA with the ATAD5 peptide (purple) has a high global similarity to the apo 
form of PCNA (grey; PDB ID: 1VYM) when superimposed with a RMSD 0.75Å over 248 
residues.  
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The binding of the peptide containing ATAD5’S PIP box to PCNA is topologically 
conserved with respect to proteins with canonical PIP boxes (65, 67–70). There are two 
main interacting regions on the peptide. The first is the PIP box region which forms a 310 
-helix with the hydrophobic residue pointing towards the minor hydrophobic groove of 
PCNA and the two aromatic residues pointing towards the major hydrophobic pocket 
(Figure 15A). The second is near the C-terminal region where Arg 67 and Thr 69 form 
hydrogen bonds with Gln 125 and Gly 127 of the IDCL (Figure 15B). The C-terminal of 
the peptide points toward the bulk solvent however, instead of interacting with amino acid 
residues along the IDCL. 
  
    
54 
 
 
 
 
 
 
 
 
 
             
  
 
 
 
 
 
 
 
 
 
Figure 15. ATAD5 binds to the hydrophobic pocket of PCNA. A) Surface representation 
of PCNA with hydrophobic areas coloured yellow and the peptide (teal) represented as 
ribbon. PIP box residues are represented as sticks. The side chains of Ile 62 faces the minor 
hydrophobic groove and the side chains of Tyr 65 and Phe 66 point toward the major 
hydrophobic pocket. B) Scheme of interactions between the synthetic peptide derived from 
ATAD5 and PCNA. Indicated are the residues (framed for PCNA), bound water (blue 
circles, hydrogen bonds (dotted lines), and non-bonded interactions (black arrows). The 
helix is shaded light blue. 
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CHAPTER 4: RESULTS II UAF1-ATAD5 INTERACTION 
 After characterizing the interaction between ATAD5’s PIP box and PCNA, we 
wanted to explore ATAD5’s interactions with UAF1. ATAD5 contains a SIM which is 
thought to interact with a SLD on the C-terminal of UAF1. In order to study this interaction, 
the genes encoding the domains of interest from the appropriate proteins were cloned into 
expression vectors. A mutation (K595E) was made to UAF1’s SLD that has been 
previously shown to reduce its binding to ATAD5. These proteins were then subsequently 
expressed and used for biochemical characterization. 
 
4.1 Expression and purification of ATAD5_SIM, UAF1_SLD2 and UAF1_SLD2M 
ATAD5_SIM, UAF1_SLD2 and UAF1_SLD2M were expressed in E. coli 
following the same growth and induction parameters. pMCSG10 encodes a N-terminally 
fused MBP tag to the protein of interest with a TEV cut site in between. The MBP tag 
contains a poly-his tag at its N-terminal allowing IMAC to be used in the purification of 
the protein of interest.    
All of the proteins were soluble and purified to near homogeneity after two rounds 
of IMAC and anion exchange chromatography. The purification of UAF1_SLD2 is shown 
in figure 16A-C as a representative purification. Clarified lysate was subjected to IMAC 
using 5 mL prepacked cOmplete His-tag purification columns (Roche). Following elution, 
TEV protease was added to the sample at a 1:40 ratio and the sample was left to dialyze 
overnight in buffer suitable for TEV protease activity (25 mM Tris pH 7.5, 150 mM NaCl, 
0.5 mM EDTA, 7 mM β-Me). The sample was then passed through the cOmplete His-tag 
purification columns (Roche), untagged proteins flowed through the column, leaving the 
His-tagged TEV protease and MBP behind. The flow-through sample was then diluted  
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Figure 16. Representative purification of tagged protein and subsequent tag cleavage by 
TEV protease. UAF1_SLD was expressed in e. coli as a MBP-fusion protein. A) SDS-
PAGE analysis of the cell lysate and soluble fraction, as well as the first IMAC step. The 
eluted proteins were pooled. B) SDS-PAGE analysis of the second IMAC step. After the 
first IMAC step, TEV protease was added and the sample was left to dialyze against ITC 
buffer (Table 1). SDS-PAGE analysis shows that the cleavage was complete. MBP tag and 
TEV were removed through another round of IMAC. C) The flow flow-through was 
subjected to anion exchange chromatography. Fraction 2 was collected and used for 
biochemical analysis. D) SDS-PAGE analysis of all GST and GST-fusion proteins used in 
pulldowns. GST-ATAD_SIM (36.1 kDa) was resolved on the gel close to the predicted 
molecular weight. ATAD_SIM (7.8 kDa), UAF1_SLD2 (13.7 kDa) and UAF1_SLD2M 
(13.7 kDa) were resolved at a slightly higher molecular weight than predicted. 
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until an appropriate NaCl concentration was reached for anion exchange chromatograph. 
Typically, 6 mg of protein was obtained from 0.5 L of culture. These proteins were resolved 
close to their predicted molecular weights during SDS-PAGE analysis and are of sufficient 
quality to be used in biochemical assays (Figure 16D).  
GST-ATAD5_SIM was purified as per “3.1.2 Expression and Purification of GST-fusion 
proteins”. To obtain ATAD5_SIM, GST-ATAD5_SIM was digested with His-tagged TEV 
at a 1:40 ratio for 2 hours at room temperature followed by 16 hours at 4 oC. The sample 
was then passed through pre-equilibrated cOmplete His-tag purification columns (Roche) 
to remove the His-tagged TEV protease and GST. ATAD5_SIM was then determined to 
be of sufficient quality by SDS-PAGE and stored at -80oC for future use (Figure 16D).  
 
4.2 GST pull-down assay 
To determine whether or not the SIM on ATAD5 interacts to the second SLD of 
UAF1, a pull-down assay was performed. A positive and negative control was included. 
The positive control consisted of GST-p21 and PCNA, which is known to interact with 
each other and has been previously demonstrated (Section 3.2). The negative control 
consisted of GST and UAF1_SLD2, this allowed us to determine if there are any non-
specific interactions between these two proteins. GST-ATAD5_SIM, GST, and GST-p21 
was immobilized to the glutathione agarose resin. Excess prey proteins were then added to 
the immobilized bait proteins. PCNA was added to GST-p21, UAF1_SLD2 was added to 
GST-ATAD5_SIM and GST and UAF1_SLD2M was added to GST-ATAD5_SIM. After 
washing off the excess proteins, the bound proteins were eluted and analyzed by SDS-  
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 INPUT OUTPUT 
GST + - - - + - - - 
GST-ATAD5_SIM - - + + - - + + 
UAF1_SLD2 + - + - + - + - 
UAF1_SLD2M - - - + - - - + 
GST-p21 - + - - - + - - 
PCNA - + - - - + - - 
                
 
Figure 17. Interaction between ATAD5’s SIM and UAF1’s SLD2 cannot be detected by 
GST pull-down assay. Excess GST or GST-fused protein was immobilized onto 15 µL of 
glutathione resin. Unbound protein was then washed off and prey proteins were added in 
excess. After several rounds of washing, bound protein were eluted from the resin and 
analyzed by SDS-PAGE on a 15 % polyacrylamide gel. GST-p21 and PCNA were used as 
a positive control for the assay. No UAF1_SLD2 band was detected in the output. 
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PAGE. SDS-PAGE analysis of the elution products did not reveal any binding to occur 
between UAF1_SLD2 and GST-ATAD5_SIM. Neither UAF1_SLD2 or UAF1_SLD2M 
were present on the output lanes of the 15 % polyacrylamide gel (Figure 17). The positive 
and negative controls both worked however. From these results, we can speculate that the 
binding between these two polypeptides are too weak to be determined by this technique 
or that they don’t interact.  
 
4.3 Isothermal titration calorimetry 
 Despite not seeing an interaction between the SIM and SLD2 of ATAD5 and UAF1 
respectively, ITC was used in order to confirm the interaction between these two proteins 
and to characterize the binding affinity. A previous study by Yang et al. (2011) 
demonstrated that UAF1 interacts with ATAD5, and loses its ability to interact upon 
deletion of the second SLD domain. Yang et al. (2011) detected the proteins using a co-IP 
assay in transfected mammalian cells, where intracellular concentrations of the proteins are 
relatively high (43). The pull-down assay performed may not have been able to detect the 
interaction due to the relatively low concentrations of proteins. Also, the pull-down assay 
may not be sensitive enough to detect weak protein interactions. Due to the potentially low 
binding affinity of the reaction, a more sensitive method is required. ITC was chosen as 
interactions in a wide range of binding affinities can be assessed, from milimolar to 
nanomolar (10-2 to 10
-9 M).  
 ATAD5_SIM was titrated into UAF1_SLD or UAF1_SLDM in order to determine 
if binding between the two proteins occur and to characterize the thermodynamic 
parameters of the interaction. High concentrations were used since no interaction was 
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detected from the pull-down experiments. 1 mM of ATAD5_SIM was loaded in the syringe 
of the NanoITC Calorimeter (TA Instruments) and titrated into the cell containing 100 M 
of UAF1_SLD or UAF1_SLDM at 25 oC. Due to the use of highly concentrated proteins, 
two control experiments were conducted: the first being buffer titrated into the cell 
containing 100 M of UAF1_SLD and the second being 1 mM of ATAD5_SIM titrated 
into buffer. The titration of buffer into the cell with UAF1_SLD did not produce significant 
heats, however, the titration of ATAD5_SIM into buffer did (Figure 18A-B). The 
experimental traces were corrected by subtracting the control measurements and analyzed 
by NanoAnalyze (TA Instruments) using an independent binding model (Figure 18C-D). 
ITC measurement of the ATAD5_SIM and UAF1_SLD reaction showed a Kd of of 19.10 
± 6.48 M, n = 0.442 ± 0.076, ∆H of -26.62 ± 7.12  kJ/mol, and a ∆S of -4.025 J/mol·K. 
ITC measurement of the ATAD5_SIM and UAF1_SLDM reaction showed a Kd of 77.82 
± 11.24 M, n = 0.142 ± 0.05, ∆H of -99.95 ± 23.4 kJ/mol, and a  ∆S of -256.6 J/mol·K.  
From the ITC experiments, it is evident that there is an interaction between the SIM 
of ATAD5 and the second SLD of UAF1. Mutation of a lysine (K595E) of UAF1 in the 
SLD2 domain reduced the binding affinity approximately 4-fold.  
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Figure 18. Determination of the thermodynamic parameters of the binding between 
ATAD5_SIM and UAF1_SLD2. Thermograms and experimental traces of various 
titrations. Buffers of proteins were exchanged by size exclusion chromatography prior to 
experiments. Titrations were performed stepwise in 2 μL injections followed by an initial 
injection of 0.48 μL at 25 oC. A) Titration of ATAD5_SIM with buffer. B) Titration of 
buffer with UAF1_SLD2. C) Titration of ATAD5_SIM with UAF1_SLD2. D) Titration of 
ATAD5_SIM with UAF1_SLD2M. 
 
  
A B 
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4.2 Crystallography 
Since we have established that the SIM from ATAD5 interacts with UAF1’s SLD2, we 
wanted to characterize the structural features of the interaction, to see if it is indeed similar 
to the interaction between SUMO and the SUMO-interacting motif. In order to do this, 
crystallization trials were initiated to determine the crystallization condition for this 
complex. Protein from the ITC experiments were concentrated to 9 mg/mL and used in 
crystallization trials. The final molar ratio of ATAD5_SIM to UAF1_SLD2 was 
approximately 3:1. Aside from sample preparation, screening was carried out as before 
using a limited number of commercial crystal screen kits. A hit was observed and 
corresponded to the condition: 0.1 M HEPES pH 7.5, PEG 8000, 8 % ethylene glycol. One 
solitary hexagonal plate was observed in this condition 2 weeks after the screen was set up 
(Figure 19A). Longer incubation of the crystal did not encourage visible crystal growth. 
The crystallization of the ATAD5_SIM:UAF1_SLD2 complex in this condition could not 
be reproduced. Varying the concentrations of the components (precipitant, buffer pH, or 
protein concentration) did not produce any crystals either. IZIT dye (Hampton Research) 
was used in order to determine whether or not the crystal was protein, as crushing of the 
crystal was undesirable. The dye was able to permeate through the solvent channels of the 
crystal, indicating it is made of protein (Figure 19B). The crystal was mounted onto a 0.05 
mm loop and streaked through the mother liquor spiked with an additional 50 % ethylene 
glycol and frozen in liquid nitrogen. Unfortunately, no diffraction was seen on the CMCF-
081D beam line at the Canadian Light Source (figure 19D). 
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Figure 19. Crystal of the complex between ATAD5_SIM and UAF1_SLD2. A) The crystal 
was grown at 18 oC from protein complex at 9 mg/mL at a ratio of 1:3 (SLD2 to SIM) in 
0.1 M HEPES pH 7.5, PEG8000, 8% ethylene glycol 3 weeks after initial set up. The 
crystal is indicated by a blue arrow. B) Attempts to reproduce the crystal were unsuccessful 
so it was tested with IZIT dye. Crystal took up the dye and was stained blue. C) The crystal 
was mounted onto a 0.05 mm loop and treated with 30 % ethylene glycol before flash 
frozen in liquid nitrogen. D) Diffraction image from the crystal. No diffraction pattern was 
observed other than from ice. 
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CHAPTER 5: DISCUSSION 
5.1 ATAD5 contains a PIP box motif 
In this work, we have demonstrated that ATAD5 contains a PIP box motif that 
mediates its interaction with PCNA. Previous reports have suggested that PCNA may 
interact with ATAD5, however, any binding had yet to be investigated. We have identified 
a PIP box in the N-terminal of ATAD5 through sequence analysis that resembles that of 
the Y-family polymerases and rfc1 of the RFC complex. ATAD5’s PIP box contains a Pro 
at position 1 of the consensus sequence instead of the canonical Gln and an Ile, Tyr, and 
Phe at positions 4, 7, and 8.  
We determined that this putative PIP box motif was able to bind to PCNA using a 
GST pull-down assay (Section 3.2) and a yeast two-hybrid system. GST-ATAD5_PIP co-
eluted with PCNA in the assay.  The amount of PCNA that co-eluted with GST-APIP 
compared to GST-p21 was significantly lower (Figure 7). This suggests that the interaction 
between PCNA and the PIP box from ATAD5 is weaker than that of p21. To confirm the 
results of the pull-down assay, the interaction was studied in a yeast two-hybrid system. 
Yeast cells were transformed with plasmids expressing recombinant protein fused to either 
the BD or AD of the transcriptional activator protein Gal4 and spot plated to determine the 
phenotype of the resultant yeast. Consistent with the previous results, yeast cells co-
transformed with the native N-terminal 250 amino acids of ATAD5 and PCNA showed the 
phenotype indicative of interaction and were able to grow on the desired selection media.  
Mutation of the conserved PIP box residues (at position 4, 7, and 8) to Ala abolishes 
the interaction between ATAD5 and PCNA in both the GST pull-down assays, as well as 
the yeast two-hybrid system. The result of the experiments with the mutants agrees with 
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what is known about PIP box/PCNA interactions. Without the proteins that make up the 
“hydrophobic plug”, the interactions that stabilize the PIP box in PCNA’s hydrophobic 
pocket cannot occur. 
Taken together, our results show that the putative PIP box identified interacts with 
PCNA, and that the conserved PIP box residues are important for interaction.  
 
5.2 Comparing ATAD5’s PIP box to other known structures 
5.2.1 ATAD5 does not possess a canonical PIP box 
A reason that ATAD5’s PIP box was yet to be identified may be that it does not 
completely conform to the canonical consensus sequence (Figure 2). In the place of a Gln, 
there is a Pro at position 1 of the motif. There have been relatively few non-canonical PIP 
boxes studied where the residue at position 1 was not Gln. Many of the Y-family 
polymerases have non-canonical PIP Boxes and contain either a Lys (polymerase  and 
polymerase ) or a Met (polymerase ) at this position (65). The Gln from other PIP box 
motifs interact with the main chain carbonyl of A252 on PCNA, and a well-ordered water 
molecule bridges the O of Gln and the amide-nitrogen atom of A208 at the C-terminal end 
of the F2 strand of PCNA. Kroker et al. (2015) identified it as the second highest 
contributor to p21’s high binding affinity in an in silico alanine scanning experiment (67). 
In contrast, the Pro at position 1 of ATAD5’s PIP box does not form any hydrogen bonds 
with surrounding residues or water molecules. Previous experiments where the residue at 
position 1 is mutated to Gln to conform to the consensus sequence, the binding affinity 
between the peptide and PCNA increased 4-fold (65). The presence of a Pro instead of a 
Gln may contribute to the lower binding affinity observed between ATAD5’s PIP box and 
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PCNA. Proline is a proteinogenic amino acid with a secondary amine, so the α-amino group 
is part of the side chain. This property usually causes disruption to the secondary structure 
of proteins. 
Interestingly, most of the polymerases that are involved in TLS do not have 
canonical PIP boxes and have alternative amino acids at position 1. ATAD5, which is 
responsible for deubiquitinating of PCNA and controlling retention of TLS polymerases 
on the replication fork also does not have the conserved Gln at position 1 either. There is 
currently no data to ascertain the significance of why these proteins involved in the DNA 
damage tolerance pathways contain non-canonical PIP boxes.  
 
5.2.2 ATAD5’s PIP box binds PCNA in a topologically conserved manner 
The binding of ATAD5’s PIP box is topologically conserved, many other crystal 
structures of peptides containing PIP boxes derived from other proteins in complex with 
PCNA show the formation of the characteristic hydrophobic plug where residues at 
position 4, 7, and 8 interacts with the hydrophobic pocket (47, 64, 65). Despite being 
predicted to be disordered, ATAD’s PIP box confers a 310 -helix structure when bound to 
PCNA. The PIP box forms a “hydrophobic plug” that interacts with a hydrophobic pocket 
on PCNA (Figure 15A). Figure 20A shows a superposition of known structures of PIP box 
binding with PCNA. As seen in Figure 15A, hydrophobic residue I62 points towards the 
minor hydrophobic groove of PCNA and the two aromatic residues (Y65 and F66) point 
towards the major hydrophobic pocket.  
The three residues at positions 4, 7, and 8 are important for the interaction with 
PCNA, and it has been hypothesized that the identities of these residues are responsible for  
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Figure 20. Comparison of human PIP box binding to PCNA. A) Cartoon representation of 
PCNA monomer (from this study, in gray) and the superposition of PIP boxes after 
structural alignment against other structures of PIP box peptides binding to PCNA. Peptide 
derived from ATAD5 is shown in yellow, other structures represented in this diagram are: 
1U7B (red), 1U76 (orange), 2ZVK (green), 3P87 (cyan), 4RJF (blue), 4ZTD (purple) and 
4D2G (pink). B) Surface representation of PCNA monomer (from this study, in gray) with 
cartoon representations of peptides derived from ATAD5 in yellow and p21(PDB ID: 
1AXC) in blue. PIP box residues (labelled with respective colours) are represented as 
sticks. 
A 
B 
P59 
I62 
Y65 
F66 
Y151 
F150 
M147 
Q144 
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tuning binding affinity (67). Comparing the binding of the hydrophobic residue 
from ATAD (our structure) and p21 (PDB ID: 1AXC), p21’s PIP box packs tighter into 
the hydrophobic pocket compared to ATAD’s (Figure 20B). In our structure, the nitrogen 
from the amine group of the Ile forms a hydrogen bond with His 44 carbonyl group’s 
oxygen from PCNA in the two aromatic residues at position 7 and 8 forms many non-
bonded contacts with many of the amino acids that make up the hydrophobic pocket of 
PCNA. In the p21 structure, a well-ordered water molecule helps stabilizes the interaction 
of the peptide with PCNA by forming many non-bonded contacts with the Tyr at position 
8. Phe at this position on our structure only forms one hydrogen bond with G127 of PCNA.  
The identities of the PIP box residues that form the hydrophobic plug is only one 
factor that affects the overall binding affinity of the PIP box peptides to PCNA. Residues 
can also interact with PCNA’s IDCL.  
 
5.2.3 ATAD5 peptide’s interaction to the IDCL  
 The C-terminal of the peptide derived from ATAD5 used in our study does not have 
many amino acids that make contacts with the IDCL of PCNA compared to the peptide 
from p21. Only three residues are resolved after F66 in the C-terminal in the final structure. 
The remaining residues are most likely do not interact with PCNA and are hence too 
flexible to be seen in the structure and point toward the bulk solvent. In contrast to the p21 
peptide structure, the C-terminal of the ATAD5 peptide does appear to make extensive 
contacts with the IDCL. In p21, the C-terminal nine amino acids form a -strand that 
interacts with the IDCL. A recent article was published where in silico alanine scanning 
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identified two Arg residues four amino acid residues downstream from the last PIP box 
residue that contribute to p21’s high binding affinity (71). 
The resolved residues that follow the last PIP box residue (RKT) interact with 
PCNA’s IDCL. Four hydrogen bonds exist here: Arg forms two hydrogen bonds with Gly 
127 between an oxygen from their carboxyl and nitrogen from their amine groups. 
Threonine also forms two hydrogen bonds, one between its nitrogen-amine group and an 
oxygen from the carboxyl group of Gln 125, and the second between O1 and the nitrogen 
amine group of Gly 127. It is interesting that the residues after position 8 form more 
hydrogen bonds with the IDCL of PCNA than the aromatic residues in the PIP box. 
Therefore, it is important to not only take into consideration the binding of the hydrophobic 
pocket but the IDCL as well when designing agents to inhibit PCNA binding.  
 
5.3 UAF1 interacts with ATAD5  
 Prolonged replication by TLS polymerases may become a source of mutations, so 
regulation of their lifespan on the replication machinery is critical. Removal of ubiquitin 
from PCNA facilitates the switching from TLS polymerases to regular high-fidelity 
polymerases. ATAD5 contains a SIM in its N-terminal domain that recruits the DUB 
complex UAF1-USP1. We wanted to characterize this interaction to assess ATAD5’s 
ability to act as an adapter between ubiquitinated PCNA and UAF1. ATAD5 may form a 
complex with UAF1 that can compete with the binding of Y-family polymerases to 
ubiquitinated PCNA.  
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5.3.1 UAF1_SLD2/ATAD5_SIM interaction was not detectable in affinity pull-down 
assay 
The interaction between ATAD5’s SIM and UAF1’s second SLD could not be 
detected in our affinity pull-down assays. No interaction was detected as UAF1’s SLD2 
did not co-eluted with GST fused to ATAD5’s SIM. There are several reasons for this 
occurrence. Firstly, the GST-affinity pull-down technique is more suited for stronger 
interactions, weak or transient interactions may not be detected by this method. Secondly, 
the cloned portion of the SIM is not sufficient to facilitate interaction, only 39 amino acids 
(the SIM was flanked by ten amino acids) were amplified out of ATAD5; this may not be 
enough for it to fold correctly. Lastly, Yang et al. (2011) studied this interaction using co-
IP experiments using extracts from cells transfected with the proteins of interest (where 
intercellular concentrations were high) (43). Additional cofactors may be present in the cell 
extract that facilitates the binding.  
 
5.3.2 ITC reveals µM binding between UAF1_SLD2 and ATAD5_SIM 
Despite not seeing a positive result from the pull-down assays, the interaction 
between ATAD5_SIM and UAF1_SLD2 was determined to have a Kd of 19.1 ± 6.48 µM. 
ITC experiments can detect a wide range of binding affinities (from nM to mM). With the 
assumption that the protein is weak (from the GST pull-down experiments), we used high 
concentrations of proteins. ATAD5_SIM was loaded into the syringe and titrated into a 
cell containing UAF1_SLD2. The Kd of this reaction was approximately 3-4 fold lower 
than the ATAD5 PIP box/PCNA interaction. The binding affinity seen in the ITC 
experiments were not completely unexpected. Lee et al. (2010) found that the chromatin-
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bound USP1 level was not changed after ELG1 knockdown and USP1 or UAF1 foci was 
not formed in response to DNA damage (72). Mutation of a lysine important for the 
interaction between ATAD5 and UAF1 resulted in a 4-fold reduction in binding affinity, 
the dissociation constant of this reaction was found to be 77.82 ± 11.24 M. This result 
agrees with the observations made by Yang et al. (2011) where they observed a reduction 
in ATAD5 binding to UAF1 bearing the same mutation (43).  
We were able to determine that UAF1 binds to ATAD5’s SIM in the low µM range. 
The binding affinity between these proteins is reduced upon mutation of a lysine on UAF1. 
Our experiments contribute to the confirmation that the binding between the SLD2 
sequence of UAF1 with ATAD5’s SIM has conserved binding characteristics to known 
SUMO/SIM interactions previously described in the literature (73).  
 
5.4 Functional implications 
 Many proteins interact with PCNA by the way of the PIP box motif. Almost 200 
different biological PIP boxes have been proposed from a bioinformatics analysis. From 
the data available, not all PIP boxes interact with the same affinity (Table 5). The variations 
of the amino acid at each position allows for the “tuning” of the binding affinities, possibly 
linking it to the protein’s function (67). What guides the binding of various proteins to 
PCNA during different pathways is unclear, as PIP boxes binding to PCNA’s hydrophobic 
pocket with low affinity can be displaced those of higher affinity, such as p21’s PIP box 
(47).  
 PCNA-PIP box interactions may not have been optimized for high affinity during 
evolution. PCNA is thought to be a “toolbelt” for replication machinery, allowing multiple 
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Table 5. Summary of PIP box-containing peptides from crystal structures available from the Protein Data Bank (www.pdb.org). 
Positions 1, 4, 7 and 8 of the PIP box consensus sequence are bolded. 
 
 
PDB ID Author Peptide Sequence Kd Ligand Notes 
4ZTD S. Hoffmann(69) KQRVRVKTVPSLFQAKLDTFLWS 30.7 µM TRAIP  
4RJF A. Kroker(67) GRKRRQTSMTDFYHSKRRLIFS 82.6 nM CDK1  
4D2G A. De Biasio(68) GNPVCVRPTPKWQKGIGEFFRLS
PKDSE 
5.56 µM P15  
3P87 D. Bubeck(66) DKSGMKSIDTFFGVKNKKKIGKV N/A RNASEH2B  
2ZVL A. Hishiki(65) CIKPNNPKHTLDIFFKPLTH 4.9µM Polκ  
2ZVM A. Hishiki(65) CAKKGLIDYYLMPSLST 0.29 µM Polι  
2ZVK A. Hishiki(65) CKRPRPEGMQTLESFFKPLTH 0.4 µM Polη  
1U76 J. Bruning(64) KANRQVSITGFFQRK 15.6 µM P66 1.53 µM with 
QRKRRLIFS added to C 
terminal 
1U7B J. Bruning(64) SRQGSTQGRLDDFFKVTGSL 60.0 µM FEN1  
1AXC J. Gulbis(47) GRKRRQTSMTDFYHSKRRLIFS 82.6 nM P21  
1VYJ G. 
Kontopidis(70) 
SAVLQKKITDYFHPKK 100 nM PL  
 T. Bui APPLPSNILDYFRKTSPT 6.17 µM ATAD5 From this study. 
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different proteins of the same pathway to bind. The low binding affinities afford the 
components (or tools) to be changed on the PCNA (toolbelt) scaffold, allowing it to 
facilitate a wide variety of functions while maintaining the hierarchy of binding.   
Bruning et al. (2004) reported that the PIP box from p66, a subunit of polδ, binds 
to PCNA with an affinity of 15.6 µM (64). Additional contacts outside of the PIP boxes 
exists. In vitro studies have shown that most replicative DNA polymerases have nanomolar 
affinity for the primer-template junction of DNA, but significantly less affinity for duplex. 
Polδ has significantly higher affinity for PCNA when it is loaded onto DNA due to the 
additive effects of the PIP box interaction. Reaching a lesion on DNA and stalling of the 
replication fork may disrupt its interaction with DNA, allowing other “tools” to replace 
polδ to make repairs. 
Some proteins have other domains that interact with PCNA when it is modified. 
For example, many of the Y-family polymerases contain additional ubiquitin-binding 
motifs (UBMs) in the form of ubiquitin binding zinc fingers (UBZs). These UBMs may 
allow the Y-family polymerases to bind to PCNA in place of existing proteins at stalled 
replication forks (where PCNA is monoubiquitinated). Even without the aid of the UBZ 
motif, the PIP-Boxes from Y-family polymerases have been reported to bind from 4.9 µM 
up to 290 nM (Table 5).  The additional binding between the UBMs and ubiquitin may 
facilitate the exchange of polymerases with the normal high-fidelity ones.  
We have determined that ATAD5’s PIP box binds to PCNA with low µM affinity 
(6.17  0.78 M). Since ATAD5 is also known to recruit the UAF1-USP1 DUB complex 
and knockdown of ATAD5 causes an accumulation of ubiquitinated PCNA on chromatin, 
we wanted to determine if it directly interacts with ubiquitin. We tested whether or not 
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ATAD5 contains a ubiquitin-binding domain using a yeast two-hybrid system and in silico 
sequence analysis. There did not appear to be any interaction between ATAD5 and 
ubiquitin (data not shown). As an adapter, the combination of ATAD5’s PIP box/PCNA 
and SIM/UAF1 interactions may be strong enough to displace the TLS polymerase from 
the replication fork after TLS, allowing the ubiquitin to be removed and normal high-
fidelity polymerases to continue replication. 
 
5.5 Conclusion and future directions 
We hypothesized that ATAD5 acts an adaptor that interacts with PCNA and UAF1. 
Although we did not assess whether or not ATAD5 was able to interact with these two 
proteins at the same time, we were able to characterize the interaction between its PIP box 
and SIM with PCNA and UAF1’s SLD2. In our study, we have demonstrated that ATAD5 
contains a PIP box and that it interacts with PCNA in the low micromolar range. Based on 
the comparison of PIP boxes from other human proteins, we can see that the residues that 
make up the hydrophobic plug are important for tuning the affinity of the peptide towards 
PCNA. Interactions with the IDCL are also important for binding affinity. Furthermore, 
we were able to characterize an interaction between ATAD5 and UAF1. 
A SIM on the N-terminal of ATAD5 interacts with the second SLD from UAF1. 
We have determined that the interaction between these two polypeptides have a binding 
affinity of 20 µM. A mutation on a lysine (K595) to Glu in the second SLD of UAF1 
reduced its binding affinity to PCNA 3-fold. Yang et al. (2011) initially made this mutation 
based off of a model of the SLD2 domain with SUMO-2, as the corresponding lysine is 
critical in SUMO/SIM interactions. The SUMO moiety of sumoylated proteins is able to 
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mediate enzyme-substrate interactions and is found in many protein pathways (73). 
ATAD5’s SIM may also interact with other sumo-modified proteins. It would be 
interesting to assess whether or not ATAD5’s SIM is able to interact with SUMO1-4 or if 
it is similar to FANCDI’s (another substrate of the UAF1-USP1 DUB) SIM, which 
exclusively interacts with SLDs. Finally, a crystal structure of the complex formed between 
the SIM of ATAD5 and SLD2 of UAF1 could provide mechanistic insight on how similar 
(if at all) it is to SIM-SUMO interactions.  
ATAD5 functions to recruit the UAF1-USP1 DUB complex to monoubiquitinated 
PCNA, however, it also functions to unload PCNA during DNA replication. These two 
functions are probably separate as previous studies have demonstrated that formation of 
the RFC-like complex containing ATAD5 is not required to control levels of PCNA 
ubiquitination. The C-terminal is responsible for ATAD5’s association with RFC subunits, 
however, the N-terminal 500 amino acids of ATAD5 alone, is sufficient to reduce levels 
of monoubiquitinated PCNA. It is unlikely that the PCNA unloading by the RFC-like 
complex containing ATAD5 is required in order to deubiquitinate PCNA (72). Previous 
reports have knocked down ATAD5 or used partial ATAD5 fragments in their studies (32, 
41). With the knowledge of the residues responsible for the interaction between ATAD5 
and PCNA, mutations can be made to the full-length protein and studied. Similar 
phenotypes to ATAD5 knockdown cells are expected upon DNA damage by DNA 
alkylating agents or ionizing radiation. Cells expressing mutant ATAD5 will have an 
impaired DNA damage response, leading to increased cell death. More specifically, 
monoubiquitinated PCNA will accumulate on chromatin, leading to increased mutation 
rates due to prolonged replication by Y-family polymerases and gross genomic instability. 
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Furthermore, inactive replication factories will begin to accumulate on DNA and prevent 
cell replication and eventually lead to cell death.  
Knowledge of how each residue of the PIP box, as well as the flanking residues, 
interact with PCNA will allow us to develop more effective drugs to combat cancer. 
Inhibition of PCNA at the mRNA and protein level has been shown to inhibit proliferation 
and cell growth, sensitizing cancer cells to chemotherapeutic agents. However, no clinical 
trials are being conducted on inhibitors of PCNA. Current inhibitors often have low 
potency, cell permeability, bioavailability, and undesirable off-target effects (67).  A more 
thorough understanding of the binding between PCNA and its many binding partners will 
allow for effective inhibitors to be developed.  
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APPENDIX 
 
 
 
 
Figure I. Vector map of pMCSG9 (left) and pMCSG10 (right). Unique restriction 
enzyme cutting sites are indicated along with notable features of the plasmid. Maps were 
created with SnapGene Viewer. 
 
 
 
 
Figure II. Vector map of pACT2. Unique restriction enzyme cutting sites are indicated 
along with notable features of the plasmid. Maps were created with SnapGene Viewer. 
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